154 related articles for article (PubMed ID: 23066856)
21. BRAFi-associated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature.
Ferreira J; Toda-Brito H; Moura MC; Sachse MF; Costa-Rosa J
J Cutan Pathol; 2017 Mar; 44(3):307-309. PubMed ID: 27976808
[No Abstract] [Full Text] [Related]
22. Haemorrhage due to proteolysis of FXIII and hyperfibrinolysis under vemurafenib treatment of metastatic melanoma.
Trappe R; Budde U; Zimmermann H
Thromb Haemost; 2012 Oct; 108(4):798-800. PubMed ID: 22918265
[No Abstract] [Full Text] [Related]
23. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.
Regnier-Rosencher E; Lazareth H; Gressier L; Avril MF; Thervet E; Dupin N
Br J Dermatol; 2013 Oct; 169(4):934-8. PubMed ID: 23909652
[TBL] [Abstract][Full Text] [Related]
24. Sarcoidosis associated with vemurafenib.
Adam A; Thomas L; Bories N; Zaharia D; Balme B; Freymond N; Dalle S
Br J Dermatol; 2013 Jul; 169(1):206-8. PubMed ID: 23834124
[No Abstract] [Full Text] [Related]
25. Don't miss the base - keratoacanthoma-type squamous cell carcinoma with perineural invasion during BRAF inhibitor therapy for melanoma.
Schüürmann M; Pönitzsch I; Simon JC; Ziemer M
J Dtsch Dermatol Ges; 2015 Dec; 13(12):1279-81. PubMed ID: 26612802
[No Abstract] [Full Text] [Related]
26. Vemurafenib and radiosensitization.
Boussemart L; Boivin C; Claveau J; Tao YG; Tomasic G; Routier E; Mateus C; Deutsch E; Robert C
JAMA Dermatol; 2013 Jul; 149(7):855-7. PubMed ID: 23699661
[TBL] [Abstract][Full Text] [Related]
27. A case of vemurafenib-induced polyarhritis in a patient with melanoma: how to manage it?
Babacan T; Türkbeyler IH; Balakan O; Pehlivan Y; Suner A; Kısacık B
Int J Rheum Dis; 2017 Mar; 20(3):398-401. PubMed ID: 24815010
[TBL] [Abstract][Full Text] [Related]
28. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
29. Painful nipple hyperkeratosis secondary to vemurafenib.
Carr ES; Brown SC; Fiala KH
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28211633
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.
Huang V; Hepper D; Anadkat M; Cornelius L
Arch Dermatol; 2012 May; 148(5):628-33. PubMed ID: 22431713
[TBL] [Abstract][Full Text] [Related]
31. Community experience of vemurafenib for BRAF(V600) melanoma.
Hersey P
Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506
[No Abstract] [Full Text] [Related]
32. The genesis of Zelboraf: targeting mutant B-Raf in melanoma.
Davis MJ; Schlessinger J
J Cell Biol; 2012 Oct; 199(1):15-9. PubMed ID: 23027900
[TBL] [Abstract][Full Text] [Related]
33. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
34. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
35. Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
Grey A; Cooper A; McNeil C; O'Toole S; Thompson J; Grimison P
Intern Med J; 2014 Jun; 44(6):597-600. PubMed ID: 24946815
[TBL] [Abstract][Full Text] [Related]
36. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib.
Sinha R; Edmonds K; Newton-Bishop J; Gore M; Larkin J; Fearfield L
J Clin Oncol; 2013 Jul; 31(19):e320-1. PubMed ID: 23715570
[No Abstract] [Full Text] [Related]
37. [BRAF: the pathologist's favorite oncogene].
Sabourin JC
Ann Pathol; 2013 Dec; 33(6):373-4. PubMed ID: 24331718
[No Abstract] [Full Text] [Related]
38. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
39. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
40. BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases.
Hui Ong EL; Sinha R; Jmor S; Fearfield L
Am J Dermatopathol; 2019 Mar; 41(3):214-217. PubMed ID: 30601209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
